Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03900598




Registration number
NCT03900598
Ethics application status
Date submitted
2/04/2019
Date registered
3/04/2019
Date last updated
23/05/2024

Titles & IDs
Public title
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Scientific title
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Secondary ID [1] 0 0
2018-003549-40
Secondary ID [2] 0 0
CR108587
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia, Lymphocytic, Chronic, B-Cell 0 0
Lymphoma, Non-Hodgkin 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-67856633

Experimental: Part 1 (Dose Escalation): JNJ-67856633 - Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.

Experimental: Part 2 (Cohort Expansion): JNJ-67856633 - Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.


Treatment: Drugs: JNJ-67856633
JNJ-67856633 capsule will be administered orally.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Dose-Limiting Toxicity (DLT)
Timepoint [1] 0 0
Approximately 21 days
Primary outcome [2] 0 0
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Timepoint [2] 0 0
Up to 4 years and 11 months
Secondary outcome [1] 0 0
JNJ-67856633 Plasma Concentrations
Timepoint [1] 0 0
Up to 4 years and 11 months
Secondary outcome [2] 0 0
Part 1 and Part 2: Overall Response Rate (ORR)
Timepoint [2] 0 0
Up to 4 years and 11 months
Secondary outcome [3] 0 0
Part 1 and Part 2: Complete Response Rate
Timepoint [3] 0 0
Up to 4 years and 11 months
Secondary outcome [4] 0 0
Part 1 and Part 2: Time to Response (TTR)
Timepoint [4] 0 0
Up to 4 years and 11 months
Secondary outcome [5] 0 0
Part 1 and Part 2: Duration of Response (DoR)
Timepoint [5] 0 0
Up to 4 years and 11 months

Eligibility
Key inclusion criteria
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

- Cardiac parameters within the following range: corrected QT interval (QTc intervals
corrected using Fridericia's formula [QTcF]) less than or equal to (<=)480
milliseconds based on the average of triplicate assessments performed no more than 5
minutes apart (plus minus [+-]3 minutes)

- Women of childbearing potential must have a negative highly sensitive serum (Beta
human chorionic gonadotropin) at screening and prior to the first dose of study drug,
and until 30 days after the last dose

- In addition to the user-independent, highly effective method of contraception, a male
or female condom with or without spermicide is required, example, condom with
spermicidal foam/gel/film/cream/suppository. Male condom and female condom should not
be used together (due to risk of failure with friction)

- Men must wear a condom when engaging in any activity that allows for passage of
ejaculate to another person. Male participants should also be advised of the benefit
for a female partner to use a highly effective method of contraception as condom may
break or leak
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known active central nervous system (CNS) involvement for dose escalation and specific
expansion cohorts as determined by the study evaluation team (SET)

- Prior solid-organ transplantation

- Either of the following: a) Received an autologous stem cell transplant less than or
equal to (<=)3 months before the first dose of study drug. b) Prior treatment with
allogenic stem cell transplant <=6 months before the first dose of study drug, has
evidence of graft versus host disease, or requires immunosuppressant therapy for graft
versus host disease within the last 4 weeks

- History of malignancy (other than the disease under study in the cohort to which the
participant is assigned) within 1 year prior to the first administration of study
drug. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in
situ of the cervix, or malignancy which in the opinion of the investigator, with
concurrence with the sponsor's medical monitor, is considered cured with minimal risk
of recurrence within 1 year before the first dose of study drug. Concomitant
malignancies that are unlikely to progress and/or preclude evaluation of study
endpoints may be allowed after discussion with the Study Responsible Physician

- Prior treatment with a mucosa-associated lymphoid tissue lymphoma translocation
protein 1 (MALT1) inhibitor

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/01/2026
Actual
Sample size
Target
Accrual to date
Final
226
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [3] 0 0
Linear Clinical Research Ltd - Nedlands
Recruitment hospital [4] 0 0
Scientia Clinical Research - Randwick
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
3000 - Melbourne
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment postcode(s) [4] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Nebraska
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
China
State/province [5] 0 0
Nanchang
Country [6] 0 0
China
State/province [6] 0 0
Tianjin
Country [7] 0 0
China
State/province [7] 0 0
Xi'an
Country [8] 0 0
France
State/province [8] 0 0
Lille
Country [9] 0 0
France
State/province [9] 0 0
Nantes Cedex 1
Country [10] 0 0
France
State/province [10] 0 0
PARIS Cedex 5
Country [11] 0 0
France
State/province [11] 0 0
Paris
Country [12] 0 0
France
State/province [12] 0 0
Pierre Benite
Country [13] 0 0
France
State/province [13] 0 0
Toulouse
Country [14] 0 0
France
State/province [14] 0 0
Tours Cedex 9
Country [15] 0 0
France
State/province [15] 0 0
VILLEJUIF Cedex
Country [16] 0 0
Germany
State/province [16] 0 0
Münster
Country [17] 0 0
Germany
State/province [17] 0 0
Ulm
Country [18] 0 0
Greece
State/province [18] 0 0
Athens
Country [19] 0 0
Israel
State/province [19] 0 0
Jerusalem
Country [20] 0 0
Israel
State/province [20] 0 0
Ramat Gan
Country [21] 0 0
Israel
State/province [21] 0 0
Tel Aviv
Country [22] 0 0
Italy
State/province [22] 0 0
Bologna
Country [23] 0 0
Italy
State/province [23] 0 0
Milano
Country [24] 0 0
Japan
State/province [24] 0 0
Chuo Ku
Country [25] 0 0
Japan
State/province [25] 0 0
Isehara
Country [26] 0 0
Japan
State/province [26] 0 0
Nagoya-shi
Country [27] 0 0
Japan
State/province [27] 0 0
Okayama
Country [28] 0 0
Japan
State/province [28] 0 0
Tokyo
Country [29] 0 0
Korea, Republic of
State/province [29] 0 0
Seoul
Country [30] 0 0
Spain
State/province [30] 0 0
Badalona, Barcelona
Country [31] 0 0
Spain
State/province [31] 0 0
Barcelona
Country [32] 0 0
Spain
State/province [32] 0 0
Madrid
Country [33] 0 0
Spain
State/province [33] 0 0
Pamplona
Country [34] 0 0
Spain
State/province [34] 0 0
Pozuelo de Alarcon
Country [35] 0 0
Spain
State/province [35] 0 0
Salamanca
Country [36] 0 0
Spain
State/province [36] 0 0
Santander
Country [37] 0 0
United Kingdom
State/province [37] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum
tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin
lymphoma and chronic lymphocytic leukemia.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03900598
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03900598